Anti-TNF-associated immunogenicity: use a retroactive drug but a proactive approach
- PMID: 32680844
- DOI: 10.1136/gutjnl-2020-322302
Anti-TNF-associated immunogenicity: use a retroactive drug but a proactive approach
Keywords: IBD clinical; TNF-ALPHA; azathioprine.
Conflict of interest statement
Competing interests: AS has received educational support from Pfizer. PDC has served as a consultant, an advisory board member or a speaker for AbbVie, Baxter, Ferring, Janssen, Shire and Takeda, and received research support from Ferring, Shire, Janssen, AbbVie and Takeda. DRVL has received educational grants or research support from Pfizer, Takeda, Ferring, Shire and has received consultancy and/or speaker’s fees from Pfizer, Janssen, Abbvie, Ferring, Vifor and Emerge Health.
Comment on
-
Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.Gut. 2020 Jul;69(7):1206-1212. doi: 10.1136/gutjnl-2019-319758. Epub 2020 Jan 24. Gut. 2020. PMID: 31980448 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical